Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Clinical Publication



  • Aprocitentan (Tryvio)

    The U.S. Food and Drug Administration (FDA) has approved a first-in-class endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled with other antihypertensives.

  • The Globe May Be Warming, but People Are Cooler

    What is normal? Patients like to tell me their normal temperature is “not normal.” Our idea of a normal temperature came from the work of a German physician who screened 25,000 patients and concluded in an 1868 publication that the normal human body temperature was 98.6°F. That number has stuck with us for 150 years. Are people now cooler?

  • Rapid Reversal of Anticoagulation Reduces Mortality from Intracerebral Hemorrhage

    Intracerebral hemorrhage (ICH) is the deadliest type of stroke. ICH associated with anticoagulation carries an even higher mortality. Serial imaging studies have demonstrated that there is significant hematoma enlargement during the first few hours after arrival at the hospital, and this also portends a poor outcome.

  • Stress Reduction for Physicians — What Works?

    A randomized controlled study of 129 physicians demonstrated that a two-month regimen of sudarshan kriya yoga, incorporating stretching, breathing, and meditation, is associated with reduced stress, anxiety, and depressive symptoms when compared to conventional stress management training.

  • Does Calcium Intake Cause Cardiovascular Disease?

    A large population study of calcium intake at dinner vs. breakfast showed an increased risk of heart disease.

  • Results from GLP-1 Receptor Agonists in Early Parkinson’s Disease

    This paper demonstrated that after one year of treatment, lixisenatide resulted in less progression of motor disability. Longer studies are needed to determine if this represents true disease modification.

  • Brentuximab Neuropathy

    Brentuximab, an antibody-drug conjugate for the treatment of lymphomas, carries a high risk of inflammatory sensory and motor neuropathies.

  • Risk of Autism After Prenatal Topiramate, Valproate, or Lamotrigine Exposure

    The incidence of autism spectrum disorder was higher among children with prenatal exposure to the topiramate, valproate, and lamotrigine than the risk in the general population. However, after adjustment for indication of the medication (epilepsy) and other confounders, an increased risk was only observed in children with prenatal exposure to valproate.

  • Seizures in Adolescents: Motor or Nonmotor?

    The rate at which motor vs. nonmotor seizures are recognized in adolescents is unknown. This retrospective analysis demonstrates a high rate of misrecognition of nonmotor seizures among adolescents presenting to an emergency department and frequent misrecognition of any nonmotor seizures in those presenting with a first-time motor seizure.

  • Novel Gene Therapy for Giant Axonal Neuropathy

    The authors conducted a Phase I trial of a gene editing approach delivered by adeno-associated virus vector carrying a codon-optimized human giant axonal neuropathy transgene. The transgene targets anterior horn motor neuron bodies and sensory neurons in the dorsal root ganglia with the goal of repairing peripheral nerves and their axons. Each patient received a single intrathecal injection of the investigational agent. At one year, patients had less progression of disease compared to pretreatment intervals.